 |
Glycosmedia
- weekly publication |
| |
Due to lack of funding Glycosmedia will now
be published weekly. If we can raise sufficient income we will
revert back to a daily publication. We would welcome offers of
advertising, sponsorship or educational grants. Glycosmedia now
has 1,282 subscribers. Please contact us for information (Editor) |
| |
|
|
Israel
and Australia's Partnership for a Cause |
| |
Diabetes has become a crippling problem for
the pacific Islands, which has recorded one of the highest rates
of the disease in the world (Israel in Focus) |
| |
|
|
Supporting
children and young people with diabetes: guidance for nurses
in schools and early years settings |
| |
This publication aims to ensure that children
and young people with diabetes receive appropriate care without
prejudicing their health or education. 14-page PDF (RCN, UK) |
| |
|
|
Initial
insulin therapy in children and adolescents with type 1 diabetes
mellitus |
| |
The predictive factors of insulin requirement
may exert beneficial effects on the assessment and adjustment of
insulin therapy in young diabetic subjects at disease onset. On
the basis of a multiple, linear regression, we suggest a formula
to calculate the initial insulin therapy (Pediatric Diabetes) |
| |
|
|
Child
obesity drug use 'soaring' |
| |
The number of under-18s in the UK being prescribed
weight-loss drugs rose 15-fold between 1999 and 2006, a study of
data from GPs suggests (BBC, UK) |
| |
|
|
Stomach
stapling and diabetes |
| |
This does not mean that weight-loss surgery
is the solution to diabetes. Bariatric surgery is only ever performed
as a last resort in morbidly obese people who fulfil the following
strict criteria as defined by NICE (NHS Choices, UK) |
| |
|
|
Low-Fat
versus Low-Carbohydrate Weight Reduction Diets: Effects on Weight
Loss, Insulin Resistance and Cardiovascular Risk A Randomised
Control Trial |
| |
This study demonstrates comparable effects on
insulin resistance of low-fat and low-carbohydrate diets independent
of macronutrient content. The difference in augmentation index
may imply a negative effect of low-carbohydrate diets on vascular
risk (Diabetes) |
| |
|
|
4
year follow-up of Diamyd® Phase II study shows clear positive trend |
| |
Diamyd Medical announced today that the company's
4-year follow-up of type 1 diabetes patients included in the company's
Phase II study shows a clear positive trend (Diamyd Medical) |
| |
|
|
Hikma
boosted by diabetes medicines |
| |
Increasingly westernised lifestyles amongst
people in the Middle East have boosted profits at Hikma Pharmaceuticals
amidst higher margins and increased sales of hypertension and diabetes
drugs (Financial Times, UK) |
| |
|
|
Big
stage for diabetes hopeful |
| |
Recent regulatory setbacks aside, Takeda Pharmaceutical
Co. is plowing full steam ahead on its quest to win approval for
the company’s key type 2 diabetes drug alogliptin, another potential entrant into the suddenly
competitive field of DPP-4 inhibitors (PharmaLive) |
| |
|
|
Takeda
Initiates Cardiovascular Outcomes Trial for Alogliptin |
| |
The U.S. Food and Drug Administration has agreed
to the study design for a cardiovascular outcomes trial titled
EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs.
Standard of CarE in Patients with Type 2 Diabetes Mellitus and
Acute Coronary Syndrome) foralogliptin (PharmaLive) |
| |
|
|
New
service to link people with type 1 to clinical trials |
| |
This online service is designed to help people
with type 1 and their families better understand the clinical trial
landscape. We also want to give you the information you need to
make a decision about taking an active role in the search for the
cure (JDRF) |
| |
|
|
New
Diabetes Device May Be Next Step in Quest for Artificial Pancreas |
| |
This new device, now available in more than
50 countries outside of the United States, can automatically suspend
insulin delivery when the device senses that glucose levels have
fallen to or below a user-selected threshold (Business Wire) |
| |
|
|
Diabetes
UK Chief Medical Advisor appointed |
| |
Dr Brian Karet has been appointed Diabetes UK
Chief Medical Advisor (Primary Care), a newly-created position
jointly sponsored by Diabetes UK and the Royal College of General
Practitioners (Diabetes, UK) |
| |
|
|
GI
News |
| |
September 2009 |
| |
|
